FilingReader Intelligence
Wantai Biopharma forecasts significant half-year loss for 2025
July 14, 2025 at 05:06 PM UTC•By FilingReader AI
Beijing Wantai Biological Pharmacy Enterprise anticipates a net loss of 13-16 million yuan for the first half of 2025. The downturn stems from industry policy adjustments and market competition impacting vaccine sales, alongside government procurement price reductions affecting IVD sales.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SSE:603392•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Beijing Wantai Biological Pharmacy Enterprise publishes news
Free account required • Unsubscribe anytime